Provention Bio
United States
189 articles about Provention Bio
-
Provention Bio Announces Pricing of $95.7 Million Public Offering of Common Stock
6/18/2020
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced the pricing of its previously announced underwritten public offering of 6,600,000 shares of its common stock at a public offering price of $14.50 per share.
-
Provention Bio Announces Proposed Public Offering of Common Stock - June 16, 2020
6/16/2020
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that it has commenced an underwritten public offering of 5,500,000 shares of its common stock.
-
Provention Bio to Present at the Jefferies Virtual Healthcare Conference
5/28/2020
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020, at 8:30 am E.T.
-
Provention Bio Announces Changes to its Board of Directors
5/20/2020
Nancy Wysenski, a Seasoned Pharmaceutical Executive with Rare Disease and Commercialization Experience, Appointed as a New Director
-
Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine
5/18/2020
The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models
-
Provention Bio Reports First Quarter 2020 Financial Results and Provides Business Update
5/7/2020
Company on Track to Complete Submission of Rolling Biologics License Application for Teplizumab in Q4 2020
-
Provention Bio to Report First Quarter 2020 Financial Results and Host Conference Call on Thursday, May 7, 2020
4/30/2020
Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that it will report its first quarter 2020 financial results on Thursday, May 7, 2020.
-
Provention Bio Initiates Rolling Submission of Biologic License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
4/16/2020
Provention Bio, Inc. announced the initiation of the rolling submission of the Company's Biologic License Application to the U.S. Food and Drug Administration for teplizumab, an anti-CD3 monoclonal antibody for the delay or prevention of clinical Type 1 Diabetes in at-risk individuals, as indicated by the presence of two or more T1D-related autoantibodies.
-
Provention Bio Provides Update on the Status of Its Phase 3 PROTECT Study for the Treatment of Newly Diagnosed Type 1 Diabetes
3/16/2020
- PROTECT Study Randomization to be Paused Temporarily in Response to the Ongoing Public Health Crisis - Company Reaffirms it is on Schedule to Complete PRV-031 (teplizumab) Rolling BLA Submission for Prevention or Delay of T1D in At-risk Individuals
-
Provention Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
3/12/2020
Provention Bio, Inc.today report financial results for fourth quarter and full year ended December, 2019.
-
Provention Announces Positive Data from Phase 1b PREVAIL Study of PRV-3279
3/12/2020
Positive data from Phase 1b preventing immune-mediated diseases.
-
Provention Bio to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, March 12, 2020
3/5/2020
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its fourth quarter and full year 2019 financial results on Thursday, March 12, 2020.
-
Provention Bio to Present at Upcoming Conferences
2/19/2020
OLDWICK, N.J. , Feb. 19, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at two upcoming conferences: The 9 th Annual SVB Leerink Global Healthcare Conference on Wednes
-
Provention Bio Highlights Critical New Research Studies on Type One Diabetes
2/6/2020
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today highlighted several new research studies on the increasing prevalence of type one diabetes (T1D) and the importance of screening for this life-impacting and life-threatening autoimmune disease.
-
BioSpace Movers & Shakers, Jan. 10
1/10/2020
Pharma and biotech companies bolster their executive leadership teams and boards of directors with this week's appointments. -
Provention Bio Appoints Jason Hoitt as Chief Commercial Officer
1/8/2020
Provention Bio, Inc. announced the appointment of Jason Hoitt as Chief Commercial Officer.
-
Janssen will assist with transferring the manufacturing rights of PRV-6527 to either Provention for continued development or assist in the transference of rights to a third party.
-
Provention Bio Reiterates Regulatory Guidance for PRV-031 (Teplizumab) Following Meeting with the FDA
12/12/2019
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it completed a Type B multidisciplinary meeting with the U.S. Food and Drug Administration (FDA) to discuss the proposed contents of a Biologics License Application (BLA) for PRV-031 (teplizumab) for the prevention or delay of type 1 diabetes (T1D) in individuals at-risk of developing T1D
-
Provention Bio Reports Third Quarter 2019 Financial Results
11/5/2019
Meeting with FDA for PRV-031 (Teplizumab) Scheduled for Fourth Quarter 2019; BLA Submission Targeted for Fourth Quarter 2020